HER2 Circulating Tumor Cells in Gastric Cancer

Samsung Medical Center135 enrolled

Overview

The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.

We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.

Study Type

OBSERVATIONAL

Enrollment

135

Conditions

Gastric Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients older than 18 years ② Patients with localized, histologically confirmed gastric cancer ③ Informed consent form Exclusion Criteria: * No informed consent form

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

To survey the frequency of HER2(+) CTC in gastric cancer

Time frame: 24month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.